Dashboard
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 2.24%
- Poor long term growth as Operating profit has grown by an annual rate 3.71% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.97
Flat results in Sep 26
Stock is technically in a Mildly Bearish range
With ROE of 0.6, it has a Very Expensive valuation with a 0.3 Price to Book Value
Stock DNA
Non Banking Financial Company (NBFC)
INR 31 Cr (Micro Cap)
53.00
19
0.00%
-0.33
0.59%
0.31
Total Returns (Price + Dividend) 
Biogen Pharma for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Biogen Pharmachem Industries Ltd Valuation Shifts Signal Elevated Price Risk
Biogen Pharmachem Industries Ltd, a micro-cap player in the Non Banking Financial Company (NBFC) sector, has seen its valuation parameters deteriorate sharply, moving from a 'risky' to a 'very expensive' rating. With a price-to-earnings (P/E) ratio soaring to 45.39 and a price-to-book value (P/BV) of just 0.27, investors face a complex valuation landscape amid weak returns and negative capital employed metrics.
Read More
Biogen Pharmachem Industries Ltd Falls to 52-Week Low of Rs 0.24 as Sell-Off Deepens
For the second consecutive session, Biogen Pharmachem Industries Ltd has seen its share price decline further, hitting a fresh 52-week low of Rs 0.24 on 15 Oct 2026. This drop extends the stock’s year-long slide, which now stands at a steep 64.79% loss, significantly underperforming the Sensex’s 11.24% decline over the same period.
Read More
Biogen Pharmachem Industries Ltd is Rated Strong Sell
Biogen Pharmachem Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 September 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 08 October 2026, providing investors with the latest insights into its performance and outlook.
Read More Announcements 
Disclosure Under Regulation 32(1) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015
03-Nov-2026 | Source : BSEPFA
Board Meeting Outcome for Outcome Of Board Meeting Held On 03Rd November 2026.
03-Nov-2026 | Source : BSEPursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Board of Directors of the Company in their meeting held on today i.e. Tuesday 03rd November 2026. at the Registered Office of the Company and transacted the following major businesses:
Regulation 33 Read With Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 ("Listing Regulations")
03-Nov-2026 | Source : BSEPFA
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
Biogen Pharmachem Industries Ltd has announced 1:6 bonus issue, ex-date: 15 May 26
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Non Institution
None
Held by 0 Schemes
Held by 0 FIIs
None
Omega Coal Private Limited (5.05%)
77.27%
Quarterly Results Snapshot (Standalone) - Sep'26 - YoY
YoY Growth in quarter ended Sep 2026 is 0.00% vs 0.00% in Sep 2025
YoY Growth in quarter ended Sep 2026 is 153.06% vs 51.00% in Sep 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024
Growth in half year ended Sep 2025 is 173.28% vs -202.65% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 0.00% vs 0.00% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 189.12% vs -223.53% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 0.00% vs 0.00% in Mar 2025
YoY Growth in year ended Mar 2026 is 396.55% vs -115.03% in Mar 2025